Brain Stem Neoplasm clinical trials at UCSF
1 in progress, 1 open to new patients

  • Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

    open to eligible people ages 12 months to 21 years

    This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.

    San Francisco, California and other locations

© The Regents of the University of California